AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD
Phase 3
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2007-01-09
- Last Posted Date
- 2010-09-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1200
- Registration Number
- NCT00419744
- Locations
- 🇻🇪
Research Site, Distrito Capital, Caracas, Venezuela
Study to Assess Safety of AZD7762 Administered Alone and in Combination With Gemcitabine in Patients With Advanced Solid Malignancies
- First Posted Date
- 2006-12-20
- Last Posted Date
- 2010-12-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 42
- Registration Number
- NCT00413686
- Locations
- 🇺🇸
Research Site, Detroit, Michigan, United States
Evaluation of 24-Hour Intragastric pH Using Esomeprazole, Lansoprazole, and Pantoprazole in Hispanic Patients With GERD
Phase 4
Completed
- Conditions
- Gastroesophageal Reflux Disease
- First Posted Date
- 2006-12-13
- Last Posted Date
- 2009-03-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 90
- Registration Number
- NCT00410592
- Locations
- 🇵🇷
Research Site, San Juan, Puerto Rico
🇺🇸Research SIte, Chapel Hill, North Carolina, United States
Asthma Care With Alvesco® (Ciclesonide) in Primary Care in Adults - The ACCEPT-study (BY9010/CA-102)
Phase 4
Completed
- Conditions
- Asthma
- Interventions
- Drug: Usual Care Inhaled Glucocorticosteroids
- First Posted Date
- 2006-11-28
- Last Posted Date
- 2017-02-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1121
- Registration Number
- NCT00404547
- Locations
- 🇨🇦
"Altana Pharma/Nycomed", York, Canada
A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects
Phase 2
Completed
- Conditions
- OverweightObesity
- Interventions
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2015-03-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 258
- Registration Number
- NCT00402077
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
Efficacy and Safety Study of Esomeprazole 20mg qd vs Ranitidine 150mg Bid in Patients With an NSAID-induced Gastric Ulcer
Phase 3
Completed
- Conditions
- Gastric Ulcer
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2010-07-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 397
- Registration Number
- NCT00401752
- Locations
- 🇭🇰
Research Site, Hong Kong, Hong Kong
Efficacy and Safety Study of Esomeprazole vs Omeprazole to Treat Acute Non-Variceal Upper Gastrointestinal Bleeding
Phase 3
Completed
- Conditions
- Gastrointestinal Hemorrhage
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2009-03-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 440
- Registration Number
- NCT00402259
- Locations
- 🇨🇳
Research Site, Tianjin, China
🇨🇳Research site, Fuzhou, Fujian, China
Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer
Phase 3
Completed
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Drug: FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)Drug: XELOX (Capecitabine and Oxaliplatin)
- First Posted Date
- 2006-11-14
- Last Posted Date
- 2016-12-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1254
- Registration Number
- NCT00399035
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
ORBITAL: Open-Label Primary Care Study: Rosuvastatin Based Compliance Initiatives Linked To Achievement Of LDL Goals
Phase 4
Withdrawn
- Conditions
- Primary Hypercholesterolaemia
- First Posted Date
- 2006-11-06
- Last Posted Date
- 2009-03-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1294
- Registration Number
- NCT00396240
Evaluation of the Efficacy of Rosuvastatin in Daily Practice (TARGET)
Completed
- Conditions
- HypercholesterolemiaCoronary Heart Disease
- First Posted Date
- 2006-11-06
- Last Posted Date
- 2006-11-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3889
- Registration Number
- NCT00396110
© Copyright 2025. All Rights Reserved by MedPath